title: Early rheumatoid arthritis.
abstract: BACKGROUND
  This review outlines current knowledge of diagnosis, assessment, treatment and risk factors for early rheumatoid arthritis (RA).
  
  
  METHODS
  Selective review of current literature was obtained by searching the terms 'rheumatoid arthritis' and 'early'.
  
  
  RESULTS
  Three issues dominate the current views on early RA. First, its recognition may be difficult. Many experts consider that early inflammatory arthritis should only be classified as RA after several months' of observation. Secondly, there is emphasis on early intensive treatment with conventional disease-modifying drugs or biologics, especially tumour necrosis factor inhibitors. Thirdly, there is a debate on the risk factors with evidence of genetic risks and environmental factors like smoking that may trigger RA. Developing citrullinated proteins followed by anti-cyclic citrullinated peptide antibodies, specific for RA, appears to be a crucial pathogenetic step.
  
  
  CONCLUSIONS
  Early RA needs immediate specialist assessment and review. Early intensive therapy is effective but needs to be focussed on patients mostly at risk of severe progressive disease.
authors.affiliation: Department of Rheumatology, King's College London, Weston Education Centre, London, UK. david.l.scott@kcl.ac.uk
authors.forename: David L
authors.initials: DL
authors.lastname: Scott
mesh_terms: D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D001688:Biological Products / Q000627:therapeutic use; D018450:Disease Progression; D042241:Early Diagnosis; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D010818:Practice Patterns, Physicians' / Q000639:trends; D012737:Sex Factors
chemical_list: D018501:Antirheumatic Agents; D001688:Biological Products